Merck & Co. (MRK)
(Delayed Data from NYSE)
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.70 USD
-1.05 (-0.96%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum C VGM
Zacks News
AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates
by Zacks Equity Research
AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.
Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails
by Kinjel Shah
AbbVie (ABBV) and Allergan (AGN) announce Q4 results.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review
by Zacks Equity Research
Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.
Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study
by Zacks Equity Research
Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.
Signs That Your Trading Will Ruin Your Retirement - February 12, 2020
by Zacks Equity Research
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
Top Stock Analyst Reports for Merck, Philip Morris & American Tower
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Philip Morris International (PM) and American Tower (AMT).
Powerful Proof Anyone Can Invest for an Early Retirement - February 11, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.
Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales
by Zacks Equity Research
Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.
Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split
by Kinjel Shah
Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.
Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.
Why Merck (MRK) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Strong Private Sector Payrolls in January
by Zacks Equity Research
Strong Private Sector Payrolls in January.
ADP Posts Blowout +291K New Jobs for January
by Mark Vickery
Monthly private-sector payrolls from Automatic Data Processing (ADP) for January posted their highest level this morning since May 2015, to a whopping 291K new private-sector jobs having been created.
Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.
Should You Buy Merck (MRK) Ahead of Earnings?
by Zacks Equity Research
Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
Merck's Recarbrio Gets FDA Priority Review for New Indication
by Zacks Equity Research
The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when Bristol-Myers (BMY) reports fourth-quarter results.
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs might demonstrate strong growth.
Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn
by Zacks Equity Research
Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced NSCLC based on data from the CheckMate-227 study.
Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.
Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter results.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports fourth-quarter 2019 results.
The Extreme Risks of Trading Your Own Retirement Assets - February 03, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.